Intracardiac Injection

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 201 Experts worldwide ranked by ideXlab platform

Michael Rosenblatt - One of the best experts on this subject based on the ideXlab platform.

  • preclinical orthotopic and Intracardiac Injection models of human breast cancer metastasis to bone and their use in drug discovery
    Current protocols in pharmacology, 2011
    Co-Authors: Ellen Scepansky, Robert Goldstein, Michael Rosenblatt
    Abstract:

    Breast cancer is the most common malignancy in women, with the development of distant metastases rendering the condition incurable. Relatively little is known about the factors governing the progression from primary tumor to metastasis, in part because of the difficulty in modeling what is a complex series of events. Detailed in this unit are descriptions of two murine models of breast cancer metastasis to bone that can be used to screen the effectiveness of new chemical entities on this disease process. Curr. Protoc. Pharmacol. 52:14.18.1-14.18.23. © 2011 by John Wiley & Sons, Inc. Keywords: breast cancer; bone metastasis; orthotopic model; Intracardiac model; bioluminescent imaging

Weiwei Wang - One of the best experts on this subject based on the ideXlab platform.

  • Intracardiac Injection of matrigel induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model.
    Journal of cellular and molecular medicine, 2010
    Co-Authors: Lailiang Ou, Dario Furlani, R Gabel, Wenzhong Li, Weiwei Wang, Yue Zhang, Heiko Sorg, Peter Mark, Christian Klopsch
    Abstract:

    Matrigel promotes angiogenesis in the myocardium from ischemic injury and prevents remodelling of the left ventricle. We assessed the therapeutic efficacy of Intracardiac matrigel Injection and matrigel-mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, matrigel (250 μl) or phosphate-buffered solution (PBS) was delivered by Intracardiac Injection. Compared to the MI control group (MI-PBS), matrigel significantly improved left ventricular function (n= 11, P < 0.05) assessed by pressure-volume loops after 4 weeks. There is no significant difference in infarct size between MI-matrigel (MI-M; 21.48 ± 1.49%, n = 10) and MI-PBS hearts (20.98 ± 1.25%, n = 10). The infarct wall thickness of left ventricle is significantly higher (P < 0.01) in MI-M (0.72 ± 0.02 mm, n = 10) compared with MI-PBS (0.62 ± 0.02 mm, n = 10). MI-M hearts exhibited higher capillary density (border 130.8 ± 4.7 versus 115.4 ± 6.0, P < 0.05; vessels per high-power field [HPF; 400×], n = 6) than MI-PBS hearts. c-Kit(+) stem cells (38.3 ± 5.3 versus 25.7 ± 1.5 c-Kit(+) cells per HPF [630×], n = 5, P < 0.05) and CD34(+) cells (13.0 ± 1.51 versus 5.6 ± 0.68 CD34(+) cells per HPF [630×], n = 5, P < 0.01) were significantly more numerous in MI-M than in MI-PBS in the infarcted hearts (n = 5, P < 0.05). Intracardiac matrigel Injection restores myocardial functions following MI, which may attribute to the improved recruitment of CD34(+) and c-Kit(+) stem cells.

  • Intracardiac Injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model
    Journal of Cellular and Molecular Medicine, 2009
    Co-Authors: Christian Klopsch, Dario Furlani, R Gabel, Wenzhong Li, Erik Pittermann, Murat Ugurlucan, Guenther Kundt, Christiana Zingler, Ulf Titze, Weiwei Wang
    Abstract:

    Erythropoietin (EPO) protects the myocardium from ischaemic injury and promotes beneficial remodelling. We assessed the therapeutic efficacy of Intracardiac EPO Injection and EPO-mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, EPO (3000 U/kg) or saline was delivered by Intracardiac Injection. Compared to myocardial infarction control group (MIC), EPO significantly improved left ventricular function (n= 11–14, P< 0.05) and decreased right ventricular wall stress (n= 8, P< 0.05) assessed by pressure-volume loops after 6 weeks. MI-EPO hearts exhibited smaller infarction size (20.1 ± 1.1%versus 27.8 ± 1.2%; n= 6–8, P< 0.001) and greater capillary density (338.5 ± 14.7 versus 259.8 ± 9.2 vessels per mm; n= 6–8, P< 0.001) than MIC hearts. Direct EPO Injection reduced post-MI myocardial apoptosis by approximately 41% (0.27 ± 0.03%versus 0.42 ± 0.03%; n= 6, P= 0.005). The chemoattractant SDF-1 was up-regulated significantly assessed by quantitative realtime PCR and immunohistology. c-Kit+ and CD34+ stem cells were significantly more numerous in MI-EPO than in MIC at 24 hrs in peripheral blood (n= 7, P< 0.05) and 48 hrs in the infarcted hearts (n= 6, P< 0.001). Further, the mRNAs of Akt, eNOS and EPO receptor were significantly enhanced in MI-EPO hearts (n= 7, P< 0.05). Intracardiac EPO Injection restores myocardial functions following MI, which may attribute to the improved early recruitment of c-Kit+ and CD34+ stem cells via the enhanced expression of chemoattractant SDF-1.

  • Intracardiac erythropoietin Injection reveals antiinflammatory potential and improved cardiac functions detected by forced swim test
    Congress of the German Transplantation Society, 2008
    Co-Authors: Dario Furlani, Christian Klopsch, Wenzhong Li, Erik Pittermann, Murat Ugurlucan, Weiwei Wang, R Gabel, Doris Klee, K Wagner, H Nizze
    Abstract:

    Systemic administration of erythropoietin (Epo) protects the myocardium from an ischemic insult and promotes beneficial remodeling. We hypothesized that Intracardiac Injection of Epo may exhibit cardioprotective potential with reduced systemic toxicity. Following myocardial infarction (MI), Epo was injected directly into the border of the infarction. Six weeks after an MI, we evaluated infarction size, angiogenesis, and pathologic effects of the treatment. Myocardial performance was assessed with a Forced Swim Test adapted to the study. Anti-inflammatory and cellular proliferative effects of Epo were analyzed by measuring expression of integrin-β and CdK4 by reverse transcriptase-polymerase chain reaction (RT-PCR). The findings indicated improved cardiac status with direct Epo administration. Exercise capacity detected by the Forced Swim Test was significantly increased. There was radical reduction of absolute infarction size, ventricular dilatation, and hypertrophy in the Epo group. Integrin-β was down-regulated and CdK4 expression was increased significantly with Epo. In conclusion, the study demonstrated that intramyocardial Epo Injection, following MI, reduced inflammation, enhanced angiogenesis and proliferation, improved myocardial functions, and did not lead to intramural thrombus formation.

Christian Klopsch - One of the best experts on this subject based on the ideXlab platform.

  • Intracardiac Injection of matrigel induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model.
    Journal of cellular and molecular medicine, 2010
    Co-Authors: Lailiang Ou, Dario Furlani, R Gabel, Wenzhong Li, Weiwei Wang, Yue Zhang, Heiko Sorg, Peter Mark, Christian Klopsch
    Abstract:

    Matrigel promotes angiogenesis in the myocardium from ischemic injury and prevents remodelling of the left ventricle. We assessed the therapeutic efficacy of Intracardiac matrigel Injection and matrigel-mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, matrigel (250 μl) or phosphate-buffered solution (PBS) was delivered by Intracardiac Injection. Compared to the MI control group (MI-PBS), matrigel significantly improved left ventricular function (n= 11, P < 0.05) assessed by pressure-volume loops after 4 weeks. There is no significant difference in infarct size between MI-matrigel (MI-M; 21.48 ± 1.49%, n = 10) and MI-PBS hearts (20.98 ± 1.25%, n = 10). The infarct wall thickness of left ventricle is significantly higher (P < 0.01) in MI-M (0.72 ± 0.02 mm, n = 10) compared with MI-PBS (0.62 ± 0.02 mm, n = 10). MI-M hearts exhibited higher capillary density (border 130.8 ± 4.7 versus 115.4 ± 6.0, P < 0.05; vessels per high-power field [HPF; 400×], n = 6) than MI-PBS hearts. c-Kit(+) stem cells (38.3 ± 5.3 versus 25.7 ± 1.5 c-Kit(+) cells per HPF [630×], n = 5, P < 0.05) and CD34(+) cells (13.0 ± 1.51 versus 5.6 ± 0.68 CD34(+) cells per HPF [630×], n = 5, P < 0.01) were significantly more numerous in MI-M than in MI-PBS in the infarcted hearts (n = 5, P < 0.05). Intracardiac matrigel Injection restores myocardial functions following MI, which may attribute to the improved recruitment of CD34(+) and c-Kit(+) stem cells.

  • Intracardiac Injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model
    Journal of Cellular and Molecular Medicine, 2009
    Co-Authors: Christian Klopsch, Dario Furlani, R Gabel, Wenzhong Li, Erik Pittermann, Murat Ugurlucan, Guenther Kundt, Christiana Zingler, Ulf Titze, Weiwei Wang
    Abstract:

    Erythropoietin (EPO) protects the myocardium from ischaemic injury and promotes beneficial remodelling. We assessed the therapeutic efficacy of Intracardiac EPO Injection and EPO-mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, EPO (3000 U/kg) or saline was delivered by Intracardiac Injection. Compared to myocardial infarction control group (MIC), EPO significantly improved left ventricular function (n= 11–14, P< 0.05) and decreased right ventricular wall stress (n= 8, P< 0.05) assessed by pressure-volume loops after 6 weeks. MI-EPO hearts exhibited smaller infarction size (20.1 ± 1.1%versus 27.8 ± 1.2%; n= 6–8, P< 0.001) and greater capillary density (338.5 ± 14.7 versus 259.8 ± 9.2 vessels per mm; n= 6–8, P< 0.001) than MIC hearts. Direct EPO Injection reduced post-MI myocardial apoptosis by approximately 41% (0.27 ± 0.03%versus 0.42 ± 0.03%; n= 6, P= 0.005). The chemoattractant SDF-1 was up-regulated significantly assessed by quantitative realtime PCR and immunohistology. c-Kit+ and CD34+ stem cells were significantly more numerous in MI-EPO than in MIC at 24 hrs in peripheral blood (n= 7, P< 0.05) and 48 hrs in the infarcted hearts (n= 6, P< 0.001). Further, the mRNAs of Akt, eNOS and EPO receptor were significantly enhanced in MI-EPO hearts (n= 7, P< 0.05). Intracardiac EPO Injection restores myocardial functions following MI, which may attribute to the improved early recruitment of c-Kit+ and CD34+ stem cells via the enhanced expression of chemoattractant SDF-1.

  • Intracardiac erythropoietin Injection reveals antiinflammatory potential and improved cardiac functions detected by forced swim test
    Congress of the German Transplantation Society, 2008
    Co-Authors: Dario Furlani, Christian Klopsch, Wenzhong Li, Erik Pittermann, Murat Ugurlucan, Weiwei Wang, R Gabel, Doris Klee, K Wagner, H Nizze
    Abstract:

    Systemic administration of erythropoietin (Epo) protects the myocardium from an ischemic insult and promotes beneficial remodeling. We hypothesized that Intracardiac Injection of Epo may exhibit cardioprotective potential with reduced systemic toxicity. Following myocardial infarction (MI), Epo was injected directly into the border of the infarction. Six weeks after an MI, we evaluated infarction size, angiogenesis, and pathologic effects of the treatment. Myocardial performance was assessed with a Forced Swim Test adapted to the study. Anti-inflammatory and cellular proliferative effects of Epo were analyzed by measuring expression of integrin-β and CdK4 by reverse transcriptase-polymerase chain reaction (RT-PCR). The findings indicated improved cardiac status with direct Epo administration. Exercise capacity detected by the Forced Swim Test was significantly increased. There was radical reduction of absolute infarction size, ventricular dilatation, and hypertrophy in the Epo group. Integrin-β was down-regulated and CdK4 expression was increased significantly with Epo. In conclusion, the study demonstrated that intramyocardial Epo Injection, following MI, reduced inflammation, enhanced angiogenesis and proliferation, improved myocardial functions, and did not lead to intramural thrombus formation.

Timothy F Witham - One of the best experts on this subject based on the ideXlab platform.

  • a novel animal model of human breast cancer metastasis to the spine a pilot study using Intracardiac Injection and luciferase expressing cells
    Journal of Neurosurgery, 2013
    Co-Authors: Patricia L Zadnik, Rachel Sarabiaestrada, Mari L Groves, Camilo A Molina, Christopher Jackson, Edward F Mccarthy, Ziya L Gokaslan, Ali Bydon, Jean Paul Wolinsky, Timothy F Witham
    Abstract:

    Object Metastatic spine disease is prevalent in cancer victims; 10%–30% of the 1.2 million new patients diagnosed with cancer in the US exhibit spinal metastases. Unfortunately, treatments are limited for these patients, as disseminated disease is often refractory to chemotherapy and is difficult to treat with surgical intervention alone. New animal models that accurately recapitulate the human disease process are needed to study the behavior of metastases in real time. Methods In this study the authors report on a cell line that reliably generates bony metastases following Intracardiac Injection and can be tracked in real time using optical bioluminescence imaging. This line, RBC3, was derived from a metastatic breast adenocarcinoma lesion arising in the osseous spine of a rat following Intracardiac Injection of MDA-231 human breast cancer cells. Results Upon culture and reInjection of RBC3, a statistically significantly increased systemic burden of metastatic tumor was noted. The resultant spine lesions...

Ellen Scepansky - One of the best experts on this subject based on the ideXlab platform.

  • preclinical orthotopic and Intracardiac Injection models of human breast cancer metastasis to bone and their use in drug discovery
    Current protocols in pharmacology, 2011
    Co-Authors: Ellen Scepansky, Robert Goldstein, Michael Rosenblatt
    Abstract:

    Breast cancer is the most common malignancy in women, with the development of distant metastases rendering the condition incurable. Relatively little is known about the factors governing the progression from primary tumor to metastasis, in part because of the difficulty in modeling what is a complex series of events. Detailed in this unit are descriptions of two murine models of breast cancer metastasis to bone that can be used to screen the effectiveness of new chemical entities on this disease process. Curr. Protoc. Pharmacol. 52:14.18.1-14.18.23. © 2011 by John Wiley & Sons, Inc. Keywords: breast cancer; bone metastasis; orthotopic model; Intracardiac model; bioluminescent imaging

Related terms

Intracardiac Injection - 15 days free trial to Access Experts & Abstracts